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Different anandamide (AEA) transport inhibitors show antinociceptive and
antiinflammatory effects in vivo, but due to their concomitant inhibition of fatty acid amide
hydrolase (FAAH) and overall poor bioavailability, they cannot be used unequivocally
to study the particular role of endocannabinoid (EC) transport in pathophysiological
conditions in vivo. Here, the potent and selective endocannabinoid reuptake inhibitor
WOBE437, which inhibits AEA and 2-arachidonoylglycerol (2-AG) transport, was tested
for its oral bioavailability to the brain. WOBE437 is assumed to locally increase EC
levels in tissues in which facilitated EC reuptake intermediates subsequent hydrolysis.
Given the marked polypharmacology of ECs, we hypothesized to see differential effects
on distinct EC receptors in animal models of acute and chronic pain/inflammation.
In C57BL6/J male mice, WOBE437 was orally bioavailable with an estimated tmax
value of ≤20 min in plasma (Cmax ∼ 2000 pmol/mL after 50 mg/kg, p.o.) and brain
(Cmax ∼ 500 pmol/g after 50 mg/kg, p.o.). WOBE437 was cleared from the brain after
approximately 180 min. In addition, in BALB/c male mice, acute oral administration of
WOBE437 (50 mg/kg) exhibited similar brain concentrations after 60 min and inhibited
analgesia in the hot plate test in a cannabinoid CB1 receptor-dependent manner,
without inducing catalepsy or affecting locomotion. WOBE437 significantly elevated
AEA in the somatosensory cortex, while showing dose-dependent biphasic effects on
2-AG levels in plasma but no significant changes in N-acylethanolamines other than
AEA in any of the tissues. In order to explore the presumed polypharmacology mediated
via elevated EC levels, we tested this EC reuptake inhibitor in complete Freud’s adjuvant
induced monoarthritis in BALB/c mice as a model of chronic inflammation. Repetitive
doses of WOBE437 (10 mg/kg, i.p.) attenuated allodynia and edema via cannabinoid
CB2, CB1, and PPARγ receptors. The allodynia inhibition of WOBE437 treatment for
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3 days was fully reversed by antagonists of any of the receptors. In the single dose
treatment the CB2 and TRPV1 antagonists significantly blocked the effect of WOBE437.
Overall, our results show the broad utility of WOBE437 for animal experimentation
for both p.o. and i.p. administrations. Furthermore, the data indicate the possible
involvement of EC reuptake/transport in pathophysiological processes related to pain
and inflammation.
Keywords: allodynia, endocannabinoids, inflammation, monoarthritis, polypharmacology, bioavailability,
endocannabinoid transport
INTRODUCTION
The endocannabinoid system (ECS) is an endogenous pan-organ
lipid signaling network that modulates numerous biological
processes, including neurotransmission, metabolism and
immune function (Maccarrone et al., 2015; Iannotti et al., 2016;
Ligresti et al., 2016). The major endogenous agonists (i.e.,
endocannabinoids, ECs) for cannabinoid receptors CB1 and
CB2 are the arachidonic acid (AA)-derived lipids 2-arachidonoyl
glycerol (2-AG) and N-arachidonoylethanolamine (anandamide,
AEA). However, these lipids also exert polypharmacological (i.e.,
pleiotropic) effects via additional proteins, including ion channels
like transient receptor potential cation channel subfamily V
member 1 (TRPV1) and peroxisome proliferator-activated
receptor gamma (PPARγ), a nuclear receptor implicated
in inflammatory processes (Di Marzo and De Petrocellis,
2012; Pertwee, 2015; Pistis and O’Sullivan, 2017; Villapol,
2018). Altered EC signaling in the brain has been associated
with nociception (Piomelli and Sasso, 2014), learning and
memory (Mechoulam and Parker, 2011), anxiety (Lisboa et al.,
2017), among others. Overall, the ECS is involved in chronic
inflammatory processes and related pain disorders (Lynch, 2016;
Barrie and Manolios, 2017; Chiurchiù et al., 2018).
The indirect modulation of EC levels is an attractive
therapeutic strategy as it may lead to fewer adverse effects
than the direct activation of CB1 receptors in terms of
neurotransmission, metabolism and immunomodulation (Di
Marzo et al., 2004). In addition to directly targeting EC receptors,
indirect cannabimimetics, e.g., inhibitors of the EC degrading
enzymes fatty acid amide hydrolase (FAAH) or monoacylglycerol
lipase (MAGL), are promising agents for the treatment of certain
types of diseases, including inflammatory pain (Chicca et al.,
2016). FAAH and MAGL inhibitors such as URB597 (Kathuria
et al., 2003) and JZL184 (Long et al., 2009a), respectively, have
been instrumental to elucidate the role of AEA and 2-AG in
animal models of anxiety and depression (Busquets-Garcia et al.,
2011; Bedse et al., 2014; Rubino et al., 2015; Zhang et al., 2015),
but also inflammatory diseases and nociception (Trang, 2007;
Woodhams et al., 2012, 2017).
Although AEA and 2-AG have different intracellular fates,
they may share a common mechanism of membrane trafficking
(i.e., facilitated cellular uptake) that is selective for ECs over
arachidonate and other N-acylethanolamines (NAEs) (Fegley
et al., 2004; Chicca et al., 2012; Nicolussi and Gertsch, 2015).
While suitable inhibitors for in vivo research are available for
most targets within the ECS (Blankman and Cravatt, 2013), the
existing AEA uptake inhibitors lack potency and show poor
selectivity over the other components of the ECS, in particular
FAAH (Fowler, 2013; Nicolussi and Gertsch, 2015). This is
potentially problematic for the interpretation of data obtained
with such inhibitors in behavioral paradigms. Conversely,
the novel EC transport inhibitor WOBE437 has been shown
to selectively block EC cellular reuptake at low nanomolar
concentrations in different cellular system in vitro and in vivo,
without targeting CB receptors, FAAH, MAGL or fatty acid
binding proteins (Chicca et al., 2017). Moreover, WOBE437 is
currently the only EC transport inhibitor shown to penetrate the
brain at bioactive concentrations (Chicca et al., 2017). Although
its molecular mechanism of action remains unknown, evidence
has been provided that it primarily acts via elevating EC levels in
tissues where EC facilitated cellular reuptake plays a role, e.g., in
the CNS or in immune cells (Chicca et al., 2017).
The majority of AEA transport inhibitors currently used exert
a range of potential therapeutic effects in animal models (Ligresti
et al., 2006; Khasabova et al., 2013; Murillo-Rodríguez et al.,
2013; Batista et al., 2014). However, AEA uptake inhibitors like
OMDM-2 (Ortar et al., 2003), UCM707 (López-Rodríguez et al.,
2001), and AM404 (Beltramo et al., 1997) are poorly selective
over FAAH and have not been tested for their oral bioavailability,
which it is presumed to be low in animal experiments because
some of these inhibitors are degraded by FAAH (Fegley et al.,
2004; Chicca et al., 2017). The natural EC reuptake inhibitor
guineensine (Nicolussi et al., 2014), despite being inactive at
FAAH, has recently been shown to exert potent antiinflammatory
effects in vivo but it also targets different CNS receptors in vitro
which might explain its CB1 receptor-independent central effects
(Reynoso-Moreno et al., 2017). Furthermore, few studies have
addressed the uptake inhibition of 2-AG, which is the major
endocannabinoid in the brain. 2-AG acts in concert with AEA,
as evidenced from differential effects between selective and non-
selective FAAH/MAGL inhibitors (Long et al., 2009b; Lau et al.,
2014).
The aim of this study was to assess the oral bioavailability of
WOBE437 to the brain and obtain data on its tissue distribution
over time. We could correlate the oral dose of WOBE437
with both its pharmacological effect in acute pain and overall
modulation of lipids related to the ECS. Here, we show that in
chronic inflammation, the action of WOBE437 is mediated via
different receptors, thus reflecting the pleiotropic action of ECs
in complex pathophysiological conditions. These data indicate
that the selective inhibition of EC reuptake could be a potential
therapeutic strategy for chronic inflammatory conditions in
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which different receptors and signaling pathways cooperate in the
etiopathology.
MATERIALS AND METHODS
Animals
Male BALB/c or male C57BL6/J mice (8–10 weeks old; 20–25 g
body weight) were either supplied by the Centro de Investigación
Biomédica de Occidente or Jackson Laboratory and kept under
standard environmental conditions (24 ± 2◦C; light–dark cycle
of 12:12 h) with food and water ad libitum. Mice were handled
according to Mexican Federal Regulations for the Care and Use
of Laboratory Animals NOM-062-ZOO-1999 (Mexican Ministry
of Health) and according to the Swiss federal guidelines, which
is in accordance with the Code of Ethics of the Directive
2010/63/EU.
Oral Bioavailability Experiments
Male C57BL6/J or male BALB/c mice were orally administered
by gavage with 10, 25, 50, or 100 mg/kg of WOBE437
(100 µL; olive oil and ethanol 8:2) using a metal feeding
needle (20G, Kent Scientific, United states). The mice were
sacrificed by decapitation after gavage administration. Brain,
blood, liver, kidney, and spleen were collected for the LC-MS/MS
analyses. All tissues were briefly washed with ice cold PBS and
immediately snap-frozen and stored at −80◦C. Whole brain
samples were dissected between the hemispheres. Blood samples
were immediately centrifuged to obtain plasma, which was stored
at−80◦C.
Quantification of WOBE437 and
Endocannabinoid Levels by LC-MS/MS
Samples extractions and LC-MS/MS measurements we
performed as previously described (Chicca et al., 2017).
Briefly, tissues were weighted and transferred in to extraction
tubes containing three steel beads and 0.1 M formic acid.
Tissues were homogenized and rapidly transferred to glass tubes
containing 1.5 mL of ethyl acetate:hexane (9:1) 0.1% formic acid
and internal standards (ISs). Samples were centrifuged and the
organic phase was recovered. After evaporation, the extracts
were reconstituted in 200 µL of ACN:ddH2O (8:2). 10 µL of the
solution were injected in the LC-MS/MS system using the same
LC and ionization protocols as described (Chicca et al., 2017).
Microsomal Clearance
Human or mice microsome clearance experiment were carried
out as according to a previously describe protocol (Soethoudt
et al., 2017). Briefly, microsome preparation (0.5 mg/mL)
plus cofactor NADPH solution was incubated with 1 µM of
WOBE437 in 96-well plates at 37◦C. After 1, 3, 6, 9, 15, 25, 35, and
45 min, 40 µL of the preparation was transferred and quenched
with 3:1 (v/v) acetonitrile containing internal standards. Samples
were then cooled and centrifuged before analysis by LC-MS/MS.
Log peak area ratios (test compound peak area/internal standard
peak area) are plotted against incubation time using a linear
fit. The calculated slope is used to determine the intrinsic
clearance. Data are obtained from single experiments measured
with multiple time-points.
Hot Plate Test
Acute pain was evaluated 1 h after gavage administration of
WOBE437, at 10, 25, 50, and 100 mg/kg in BALB/c mice. The test
was performed using a clean 54–56◦C hot plate (Thermo Fisher
Scientific, United states) with a Plexiglas cylinder. The latency
to show the first nociceptive response (paw lick or foot shake)
was measured. In order to evaluate CB1 receptor antagonism,
5 mg/kg of rimonabant (Pharmaserv AG, Switzerland) was
injected intraperitoneally (i.p.) (20 µL, in DMSO) 30 min before
WOBE437 administration.
Tetrad Test
The tetrad test was performed in the following order:
rectal temperature, catalepsy, locomotion and analgesia. Rectal
temperature was measured before (basal) and 1 h post gavage
administration by using a thermocouple probe (Physitemp
Instruments Inc., United states) and results were reported as
the difference (1) between both temperatures. The bar test was
used to evaluated catalepsy by placing the mouse in an imposed
position with both forelimbs resting on a bar of 4 cm high;
the end point of catalepsy was considered when both front
limbs were removed or remained over 120 s. Locomotor activity
was determined by placing the mouse on a rotarod (Erweka,
Germany) at 4 rpm, the latency to fall was measured with a cut-
off time of 120 s. Each mouse was previously trained to walk
over the rotarod for at least 120 s. Catalepsy and locomotion
were measured in three trials. Analgesia was evaluated with the
hot plate test, each mouse was placed in a 54–56◦C hot plate
(Thermo Fisher Scientific, United states) with a Plexiglas cylinder,
the latency to first nociceptive response (paw lick or foot shake)
was measured.
Mouse Model of Complete Freund’s
Adjuvant Induced Monoarthritis
BALB/c mice were anesthetized with xylazine/ketamine (5
and 10 mg/kg, respectively) and subsequently monoarthritis
was induced by intra-articular injection of complete Freund’s
adjuvant (CFA, 40 µL; Sigma-Aldrich, St. Louis, MO, United
states) into the right knee joint. The inflammation was allowed to
develop for 14 days prior to pharmacological treatments starting
at day 15 for 1 or 3 days, respectively. Mechanical sensitivity
(allodynia) and knee diameter (edema) were evaluated 1 h post
treatment in the ipsilateral and contralateral knees. Articular
sensitivity was evaluated using a digital algometer (Bioseb,
United states). The knee withdrawal threshold was determined
by applying slow increments of force into the joint until the
mice showed a signal of pain (withdrawal reflex or vocalization).
A cut-off force of 300 g was considered to avoid damage in
the tissue. The measurements were done in triplicates and the
average was considered for the statistical analysis. To evaluate
the degree of inflammation, knee diameter was measured in
both extremities using a digital micrometer (Mitutoyo, United
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states). WOBE437 was administered at doses of 2.5, 5, or
10 mg/kg, either as single dose or for 3 days treatment. To
evaluate the involvement of CB1 and CB2 receptors, TRPV1 and
PPARγ, rimonabant (5 mg/kg, CB1 receptor antagonist/inverse
agonist), SR144528 (3 mg/kg, CB2 receptor antagonist/inverse
agonist; Cayman Chemical, United states), capsazepine (5 mg/kg,
TRPV1 antagonist; Tocris Bioscience, United Kingdom) and
GW9662 (3 mg/kg, PPARγ antagonist; Tocris Bioscience,
United Kingdom) were injected 30 min before WOBE437
administration. Indomethacin (5 mg/kg; Sigma-Aldrich, United
states) was used as a reference drug (positive control). For all
the compounds, dimethylsulfoxide (DMSO) was used as vehicle
(20 µL, i.p.).
Open Field Test
Potential motor changes were evaluated in an open field
box (40 cm × 40 cm × 30 cm, Plexiglas). The mice were
individually placed in the center and allowed to move freely
for 5 min. The locomotion activity was recorded with the
OpenFieldTest© (Reynoso-Moreno et al., 2017) and traveled
distance was evaluated automatically. After every experiment, the
box was cleaned with 70% ethanol to remove odors.
Real-Time PCR
To evaluate gene expression of CB receptors and the main
enzymes involve in AEA and 2-AG biosynthesis, somatosensory
cortex, thalamus and knee articular tissue were recover after
3 days of treatment with vehicle or WOBE437 in the complete
Freund’s adjuvant induced monoarthritis model. Total RNA
extraction and reverse transcription were carried out with a
previously described protocol (Castro-Torres et al., 2015). The kit
LightCycler R© FastStart DNA MasterPLUS SYBR Green I (Roche,
United states) was used for the real-time PCR, according to
manufacturer protocol, and the reaction was performed in the
LightCycler 2.0 equipment (Roche, United states). The relative
gene expression was calculated by using the method known as
2ˆ(−11Ct) (Livak and Schmittgen, 2001). 11Ct was calculated
using the following formula:
11Ct= (CtTE − CtHE) − (CtTC − CtHC)
CtTE: Ct for the tested gene (Cnr1, Cnr2, Nape-pld, Dagla) in
the experimental or control group
CtHE: Ct for the housekeeping gene (Actb) in the experimental
or control group
CtTC: mean Ct for the tested gene in the control group
CtHC: mean Ct for the housekeeping gene in the control group
Finally 2ˆ(−11Ct) was calculated to obtain the fold
change of gene expression. Every sample (n = 6−15, per
group and region) was analyzed in duplicated and the
mean value was considered for 11Ct calculation. Beta-
actin was used as the housekeeping gene and mean of
vehicle group was used as a calibrator. Sequences and size
products of the primers for beta actin (Actb) cannabinoid CB1
receptor (Cnr1), cannabinoid CB2 receptor (Cnr2), diacylglycerol
lipase alpha (Dagla), N-acylphosphatidylethanolamine specific
phospholipase D (Nape-pld) are shown in Table 1.
Statistical Analysis
All data are presented as mean values± SD and were analyzed by
non-parametrical methods using a Kruskal–Wallis test followed
by Mann–Whitney U as a post hoc test. A confidence level of
p < 0.05 was considered statistically significant. Analyses were
carried out using the GraphPad Prism software version v5.0 (La
Jolla, CA, United States).
RESULTS
The Endocannabinoid Reuptake Inhibitor
WOBE437 Is Orally Bioavailable
Oral administration of WOBE437 in male C57BL6/J mice showed
a complete biodistribution after 20 min, with corresponding
brain levels of 24.7 ± 25.3 pmol/g using a dose of 10 mg/kg
and 534.5 ± 109.9 pmol/g using a dose of 50 mg/kg
(Figure 1A). In plasma, WOBE437 reached 47.3 ± 32.5
and 1731.5 ± 703.4 pmol/mL after oral doses of 10 or
50 mg/kg, respectively (Figure 1A). In order to characterize
the tissue distribution of WOBE437 over time, brain and
plasma samples were recovered at different time-points (10,
20, 40, 60, 90, and 180 min) after gavage administration
of 50 mg/kg. The highest concentration of WOBE437 was
found at ≤20 min (tmax), reaching apparent Cmax values of
471.7 ± 182.6 pmol/g in brain and 1931 ± 564 pmol/mL
in plasma, respectively (Figure 1B). The apparent volume of
distribution (Vd) at Cmax was 80.4 L/kg and at the steady state
609 L/kg, thus large and reflecting lipid solubility and massive
tissue penetration/retention. In brain, the value obtained with
50 mg/kg, p.o. is equivalent to an estimated concentration of
399.7 ± 154.7 nM. WOBE437 is cleared from the brain after
approximately 180 min. Furthermore, in kidney, liver, and spleen,
the tmax values of WOBE437 were ≤20 min after administration
(Figure 1C). The highest concentration was found in liver with
4720 ± 3273 pmol/g, followed by kidney (2277 ± 916 pmol/g)
and spleen (1030 ± 339 pmol/g). Between 20 and 40 min, the
hepatic concentration of WOBE437 showed the most significant
reduction, dropping by a factor 4 from 4720 to 1080 pmol/g
(Figure 1C). In preliminary experiments with human and mouse
liver microsomes the clearance of WOBE437 was estimated as
657 and 174 µL/min/kg, respectively (Table 2). These values
suggested an estimated maximal bioavailability of 17% in mice
and 4% in humans.
Nociceptive Effect After Single Oral Dose
of WOBE437
Since WOBE437 has previously shown analgesic effects in
different models of acute pain after single i.p. injection (Chicca
et al., 2017), we evaluated the pharmacological effects of
WOBE437 after oral administration in BALB/c male mice. In
a dose-response curve, 50 mg/kg, p.o. of WOBE437 was the
minimum dose necessary to significantly increase the pain
threshold from 5.8 ± 0.9 s in the vehicle group to 9.4 ± 1.9 s
(61.7% increase, Figure 2A). WOBE437 at 100 mg/kg, p.o.
marginally further increased the pain threshold to 11.7 ± 2.6 s,
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TABLE 1 | Sequences of primers used in the real-time PCR.
Gen Primers Product size (bp) GenBank access number
Cnr1 Sense 5′-CTT GCA GAT ACC ACC TTC CGT-3′ 142 NM_007726.3
Antisense 5′-CCC TGA AGG AAG TTA GAG GGA-3′
Cnr2 Sense 5′-GAC AGA AGT GAC CAA CGG CT-3′ 76 X93168.1
Antisense 5′-GCC ACT GCT CAG GAT CAT GT-3′
Napepld Sense 5′-GCG CCA GAA TTC AGT GCA GA-3′ 175 NM_178728.5
Antisense 5′-GAG CAC ATT CGG GAT GGA GA-3′
Dagla Sense 5′-CTC GTC CTG CCA GCT ATC TT-3′ 157 NM_198114.2
Antisense 5′-TAC AGC TCA GAA GGA TGC CC-3′
Actb Sense 5′-GGC CAA CCG TGA AAA GAT GA-3′ 77 NM_007393.5
Antisense 5′-CAG CCT GGA TGG CTA CGT ACA-3′
Actb, beta actin; bp, base of pairs; Cnr1, cannabinoid CB1 receptor; Cnr2, cannabinoid CB2 receptor; dagla, diacylglycerol lipase alpha; Napepld,
N-acylphosphatidylethanolamine specific phospholipase D (Nape-pld).
FIGURE 1 | WOBE437 is rapidly biodistributed after oral administration in C57BL6/J male mice. (A) After 20 min post-gavage, WOBE437 was dose-dependently
absorbed and reached quantifiable concentrations in brain and plasma. Data show mean values ± SD of 5–10 mice. (B) Time course of WOBE437 concentration in
brain and plasma showing an estimated Tmax of 10–20 min after administration. Data show mean values ± SD of 5–10 mice. (C) Time course of WOBE437
concentrations in kidney, liver, and spleen, showing the highest concentrations in liver 20 min after administration. p.o., per os. Data show mean values ± SD of
5–10 mice.
thus not significantly more than 50 mg/kg, with an estimated
effective dose (ED50) value of 42.5 ± 3.9 mg/kg. The analgesic
effect of WOBE437 was mediated through the CB1 receptor
as the antinociceptive effect was completely abolished after
rimonabant pre-treatment (Figures 2B,C). Additionally, the
oral administration of 50 mg/kg of WOBE437 was evaluated
in the tetrad test (Figure 3). No statistical differences were
found in body temperature, catalepsy or motor coordination,
but significant antinociception was measured. However, a
tendency to induce hypothermia (Figure 3A) and catalepsy
(Figure 3B) was observed as the body temperature decreased
from +0.1 ± 0.8◦C (control) to −0.8 ± 0.8◦C (WOBE437
50 mg/kg) and the latency of catalepsy increased from 5.9± 5.4 s
(control) to 10.5 ± 10.6 s (WOBE437 50 mg/kg). To further
characterize the effects of oral administration of WOBE437,
brain and plasma samples were collected after the hot plate test
to analyze the EC levels. In somatosensory cortex, 50 mg/kg
of WOBE437 showed a significant increase in AEA levels
(Figure 4B) but no changes in 2-AG (Figure 4A). In total
brain, WOBE437 showed a tendency to increase both AEA
and 2-AG levels (Figures 4D,E). Interestingly, in plasma we
measured a dose-dependent biphasic effect on 2-AG with a
significant rise in 2-AG levels after 50 and 100 mg/kg of
WOBE437 (Figure 4G). AEA showed a statistically significant
but slight reduction in plasma (Figure 4H). The levels of
WOBE437 were similar in somatosensory cortex, total brain
and plasma (Figures 4C,F,I) and in the same range as in
male C57BL6/J mice (Figure 1B), despite BALB/c showing
a tendency toward lower plasma levels (not statistically
significant). Overall, the oral administration resulted in high
variability of WOBE437 tissue concentrations. No changes
in the levels of N-acylethanolamines other than AEA were
measured in the somatosensory cortex, total brain or plasma
(Figure 5).
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WOBE437 Indirectly Triggers
Polypharmacological Effects in a Model
of Chronic Inflammation
Considering our previous data showing the analgesic and
antiinflammatory effects of WOBE437 after single i.p. injection
(Chicca et al., 2017) and the confirmation of CB1 receptor-
dependent antinociception after oral WOBE437 administration
(Figure 2), we decided to further evaluate its pharmacological
properties and underlying mechanism(s) in a chronic model of
inflammatory pain. After the induction of monoarthritis by intra-
articular injection of CFA in mice (Figure 6A), a single dose of
WOBE437 at 10 mg/kg, i.p., was able to significantly decrease
allodynia (Figure 6B). After 3 days treatment, allodynia was
reduced by increasing the pain threshold from 69.0 ± 15.7 g
in the vehicle group to 136. 3 ± 31.7 g in the group treated
with WOBE437 10 mg/kg, i.p., reflecting a reduction of 52% in
allodynia as compared to the contralateral knee (197.0 ± 39.6 g)
(Figure 6C). Furthermore, the inflammation (edema) was
reduced by 58% resulting in a decrease of the knee diameter
from 6.5 ± 0.9 mm in the vehicle group to 5.3 ± 0.4 mm in the
WOBE437 10 mg/kg group as compared to the contralateral knee
(4.5 ± 0.3 mm) (Figure 6D). The doses of 2.5 and 5.0 mg/kg,
i.p., did not show any significant changes. The spontaneous
motor activity was measured, but without significant observable
changes upon WOBE437 treatment. Nevertheless, a noteworthy
tendency to improve spontaneous locomotion was noticed in
the monoarthritic group treated with WOBE437 2.5 mg/kg
(Figure 6E).
In an attempt to better characterize the downstream
mechanism(s) involved in the pharmacological effects mediated
by WOBE437 in the monoarthritis model, we pre-treated the
mice with cannabinoid CB1 receptor, cannabinoid CB2 receptor,
PPARγ and TRPV1 antagonists. In the single dose experiment,
the antiallodynia effects of WOBE437 (10 mg/kg, i.p.) were
clearly mediated by cannabinoid CB2 and TRPV1 receptors
because the CB2 receptor antagonist/inverse agonist SR144528
(3 mg/kg, i.p.) and the TRPV1 antagonist capsazepine (5 mg/kg,
i.p.) completely prevented the improvement in mechanical
sensitivity by WOBE437 (Figure 7A). Conversely, the CB1
antagonist/inverse agonist rimonabant and PPARγ antagonist
GW9662 did not block the effect of WOBE437 in this experiment.
Interestingly, a clear multi-target mechanism was seen after
3 days treatment with WOBE437 10 mg/kg, i.p., because the
antiallodynia and antiinflammatory effects were fully abolished
by each of the cannabinoid CB1 receptor antagonist/inverse
agonist rimonabant (5 mg/kg, i.p.), the CB2 antagonist SR144528
(3 mg/kg, i.p.) and PPARγ antagonist GW9662 (3 mg/kg,
i.p.) (Figures 7B,C). On the other hand, the antiinflammatory
effect was only partially prevented with rimonabant and
GW9662 (Figure 7C), indicating additive contributions of CB1
and PPARγ receptors, respectively. In the 3 days WOBE437
treatment we could not use the TRPV1 antagonist capsazepine
because the mice showed an unexpected hypersensitivity. In
the monoarthritic mice, WOBE437 treatment did not lead to
any significant change in the expression of the cannabinoid
CB1 receptor (Cnr1), the cannabinoid CB2 receptor (Cnr2) or
TABLE 2 | Clearance of WOBE437 calculated after incubation for 2 h with human
and mouse liver microsomes.
Mouse Human
Clearance 174 µL/min/kg 657 µL/min/kg
MAB 17% 4%
The maximal achievable bioavailability (MAB) was estimated from the clearance.
the enzymes involved in EC production, namely diacylglycerol
lipase (Dagla) and N-acylphosphatidylethanolamine specific
phospholipase D (Nape-pld) (Figure 8), thus excluding broad
transcriptional effects on the ECS.
DISCUSSION
WOBE437 Is Orally Bioavailable to the
Brain and Exerts Cannabinoid CB1
Receptor-Dependent Antinociceptive
Effects
As outlined by Arrowsmith et al. (2015), chemical probes are
powerful tools with increasing impact on biomedical research.
However, probes and inhibitors of poor quality or that are
used incorrectly generate misleading results. Among the AEA
transport inhibitors, this problem is inherent because they do
not generally fulfill the criteria of a good chemical probe, such as
potency, selectivity and bioavailability. Importantly, none of the
AEA/EC transporter inhibitors (UCM707, OMDM-2, AM404,
guineensine) has been investigated for general bioavailability,
pharmacokinetic parameters or brain penetration by analytical
methods (see below). We recently reported the development
of WOBE437 as a novel highly potent and selective EC
reuptake inhibitor (SERI) which specifically increases/modulates
the levels of the two main ECs AEA and 2-AG in vitro
and in vivo (Chicca et al., 2017). WOBE437 showed relevant
pharmacological effects in different animal models of acute pain,
anxiety and endotoxemia, reaching bioactive concentrations in
the brain after intraperitoneal injection (Chicca et al., 2017).
Here, we assessed the basic oral bioavailability of WOBE437,
its distribution to the brain, plasma and peripheral tissues and
evaluated its corresponding antinociceptive and cannabimimetic
effects. Considering the stress induced by gavage feeding, the
hot plate assay was an ideal nociception paradigm as it avoids
chronic stress, unlike, e.g., chronic inflammation. Our results
showed quantifiable levels of WOBE437 in brain already 10 min
after oral gavage, reaching the highest concentration 20 min
after administration, with an estimated tmax of ≤20 min in
plasma (Cmax ∼2000 pmol/mL after 50 mg/kg, p.o.) and brain
(Cmax ∼500 pmol/g after 50 mg/kg, p.o.). The WOBE437
concentration in brain remained relatively stable between
300 and 400 pmol/g up to 1 h and was still detectable
3 h after administration (18 pmol/g). A control over the
bioavailability and basic pharmacokinetics requirements (e.g.,
reaching bioactive tissue concentrations) are fundamental to
understand the pharmacological effects measured in behavioral
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FIGURE 2 | Oral administration of WOBE437 attenuates acute pain in the hot plate test in BALB/c male mice in a CB1 receptor-dependent manner.
(A) Dose-response curve of WOBE437 in the pain latency response in the hot plate test. 50 mg/kg of WOBE437 p.o. was the minimum dose to significantly increase
pain threshold. The analgesic effect of (B) 50 mg/kg and (C) 100 mg/kg of WOBE437 was completely abolished by pre-treatment with rimonabant (5 mg/kg, i.p.). All
doses are expressed in mg/kg. Rimonabant was injected i.p. 30 min before gavage administration of WOBE437. Data show mean values ± SD of 5–10 mice. Data
were compared using Kruskal–Wallis test followed by Mann–Whitney test. ∗p < 0.05 vs. vehicle; #p < 0.05 vs. WOBE437; p.o. per os; ns, no significant.
FIGURE 3 | Oral administration of 50 mg/kg WOBE437 did not elicit all the effects in the tetrad test in BALB/c male mice. (A) Change in body temperature (B)
latency of catalepsy, (C) locomotion, and (D) latency of pain response 1 h after gavage administration of vehicle or 50 mg/kg of WOBE437. Data show median
percentile 25, percentile 75 minimum and maximum of five mice. Data were compared using Mann–Whitney test. ∗p < 0.05 vs. vehicle.
tests. However, the oral bioavailability of the currently used
non-selective AEA transport inhibitors remains unknown. We
and others have previously shown that AEA uptake inhibitors
like UCM707, AM404, and VDM11 are substrates for h/rFAAH
or hMAGL, which strongly suggest their metabolic instability,
i.e., degradation after systemic administration (Fegley et al.,
2004; Vandevoorde and Fowler, 2005; Chicca et al., 2017).
Conversely, WOBE437 is not affected by the hydrolytic activity
of FAAH and MAGL and is not modified by COX-2 (Chicca
et al., 2017). Nevertheless, the present data show that WOBE437
is significantly metabolized by liver microsomes (human and
mouse) after 2 h of incubation, resulting in an estimated oral
bioavailability of 4% (human) and 17% (mouse). In the hot plate
test, WOBE437 exerted significant analgesic effects at the dose of
50 mg/kg upon oral administration, while the fully effective dose
was 10 mg/kg upon systemic administration (i.p.) (Chicca et al.,
2017). This difference suggests an overall 20% bioavailability
compared to the i.p. administration route, in agreement the
estimated maximal bioavailability of 17% calculated in mouse
liver microsomes. According to these findings, one could assume
that 50 mg/kg, p.o. is almost equivalent to 10 mg/kg, i.p. (i.e.,
a factor 5). However, the brain levels were approximately 10
times lower after p.o. as compared to i.p. Our previous findings
showed that 10 mg/kg of WOBE437 i.p. induced a slight but
significant effect in the entire tetrad test battery (hypothermia,
catalepsy, hypolocomotion, and analgesia) (Chicca et al., 2017).
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FIGURE 4 | Changes in endocannabinoid levels 1 h after oral administration of WOBE437 in BALB/c male mice. In somatosensory cortex, WOBE437 did not
change (A) 2-AG levels but significantly increased (B) AEA levels with a single 50 mg/kg dose. (C) Concentration of WOBE437 in somatosensory cortex. In total
brain homogenate, (D) 2-AG and (E) AEA did not significantly change after oral administration of a single dose of 50 mg/kg of WOBE437. (F) Concentration of
WOBE437 in total brain homogenate. (G) 2-AG levels were significantly increase in plasma with a slightly decrease in (H) AEA. (I) Concentration of WOBE437 in
plasma. All data show mean values ± SD of at least 7 to 10 mice. Groups were compared using Kruskal–Wallis test followed by Mann–Whitney test. ∗p < 0.05 vs.
vehicle. 2-AG, 2-arachidonoylglycerol; AEA, anadamide; p.o. per os.
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FIGURE 5 | Levels of N-acylethanolamines 1 h after oral administration of WOBE437 in BALB/c male mice. (A) Palmitoylethanolamide (PEA), (B) oleoylethanolamine
(OEA) and (C) linoleoylethanolamide (LEA) levels in somatosensory cortex. (D) PEA, (E) OEA, and (F) LEA levels in total brain homogenate. (G) PEA, (H) OEA, and
(I) LEA levels in plasma. All data show mean values ± SD of at least 5 to 10 mice. Groups were compared using Kruskal–Wallis test followed by Mann–Whitney test.
∗p < 0.05 vs. vehicle. LOQ, limit of quantification; p.o. per os.
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FIGURE 6 | Effect of WOBE437 on allodynia and inflammation after a single dose or 3 days treatment in a mouse model of monoarthritis. (A) Treatment scheme of
monoarthritis induced by knee immunization with complete Freund’s adjuvant (CFA) (40 µL, intra-articular) in which the inflammatory process was allowed to develop
for 14 days. Intraperitoneal treatments with WOBE437 were carried on days 15 to 17. (B) Allodynia was evaluated upon single dose treatments in which 10 mg/kg of
WOBE437 increased the pain threshold. After 3 days of treatment, 10 mg/kg of WOBE437 improved (C) allodynia and reduced (D) edema. (E) The development of
monoarthritis significantly decreased the travel distance in the open field test, but no significant changes were observed after WOBE437 treatment due to high
variability. Indomethacin was used as a reference drug. All doses are shown in mg/kg, i.p. Allodynia was evaluated by mechanical sensitivity and edema through
knee diameter and both were measured 1 h after pharmacological treatments. All data show mean values ± SD of at least 6 to 15 mice. Groups were compared
using Kruskal–Wallis test followed by Mann–Whitney test. ∗p < 0.05 vs. ipsilateral/vehicle; #p < 0.05 vs. contralateral/healthy; i.p., intraperitoneally.
Therefore, we also tested the effects of 50 mg/kg of WOBE437
p.o. in BALB/c mice. However, statistical significance was only
found for analgesia 1 h after oral administration of WOBE437
but only a tendency to induce hypothermia and catalepsy. This
can be explained by the lower levels of WOBE437 in the brain.
One hour after oral administration of WOBE437 at the
single dose of 50 mg/kg, a significant increase of AEA levels in
the somatosensory cortex was measured, with only a tendency
to increase AEA in the total brain. These findings point
to a brain region-specific increment in the AEA levels, in
agreement with the different EC levels across brain regions
and changes in a tissue specific manner (González et al., 2002;
Bystrowska et al., 2014; Chicca et al., 2017). Moreover, 2-AG
concentration showed a tendency to increase in total brain,
from 10.8 ± 2.6 nmol/g to 13.9 ± 2.6 nmol/g after 50 mg/kg
of WOBE437, without significant changes in somatosensory
cortex. This lack of statistical significance in somatosensory
cortex might be due to limited involvement of 2-AG in this
area under basal conditions, because significant increase in 2-
AG levels have been shown after stress or chronic constriction
injury in dorsal midbrain and particularly in periaqueductal grey
matter (PAG) (Hohmann et al., 2005; Petrosino et al., 2007).
On the contrary, the treatment with 25, 50, and 100 mg/kg of
WOBE437 induced a significant increase by 40% of 2-AG levels
from 16.1 ± 2.9 pmol/mL to 21.4 ± 4.5 pmol/mL (25 mg/kg),
22.6 ± 4.8 pmol/mL (50 mg/kg) and 23.8 ± 5.7 pmol/mL
(100 mg/kg) in plasma. On the other hand, the concentration of
AEA in plasma was weakly but significantly reduced by 23%, from
2.6 ± 0.2 pmol/mL in the control group to 2.2 ± 0.3 pmol/mL
in the group treated with WOBE437 at 50 mg/kg. This slight
decrease in AEA levels may not cause biological effects but could
rather reflect differential AEA transport kinetics between AEA
and 2-AG in a complex tissue environment. We have previously
shown that AEA and 2-AG compete for cellular uptake in vitro
with different affinities (Chicca et al., 2012). Finally, the effects of
WOBE437 on circulating ECs upon i.p. administration exhibited
yet a different pattern leading to significant increase of 2-AG
levels as compared to vehicle (after 15 min) but without affecting
AEA levels (Chicca et al., 2017).
Selective Inhibition of Endocannabinoid
Uptake Through WOBE437 Triggers
Polypharmacological Effects in
Inflammatory Pain
To evaluate the preclinical potential of WOBE437, or in general
of selective inhibition of the EC reuptake process, chronic
inflammatory pain was induced by the intra-articular injection
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FIGURE 7 | Polypharmacological effects observed after 3 days treatment with 10 mg/kg of WOBE437. (A) The antiallodynia effects of 10 mg/kg of WOBE437 after
single dose were significantly reversed by the CB2 receptor antagonist SR144528 and the TRPV1 antagonist capsazepine. In the 3 days treatment scheme,
(B) antiallodynia and (C) the antiinflammatory effects were prevented by antagonists of the CB1 receptor (rimonabant), CB2 receptor (SR144528) and PPARγ
(GW9662). Rimonabant, SR144528 or GW9662 were administered i.p. 30 min before WOBE437. Allodynia was evaluated by mechanical sensitivity and edema
measuring knee diameter; both were assessed 1 h after WOBE437 treatment. All compounds were administered i.p. Groups were compared using Kruskal–Wallis
test followed by Mann–Whitney test. ∗p < 0.05 vs. ipsilateral/vehicle; #p < 0.05 vs. contralateral/vehicle; &p < 0.05 vs. WOBE437; i.p., intraperitoneally.
FIGURE 8 | Changes in total RNA levels of EC components after the CFA-induced monoarthritis model and 3 days treatment with WOBE437 10 mg/kg, i.p., in
BALB/c mice. Total RNA levels of cannabinoid CB1 receptor (Cnr1), cannabinoid CB2 receptor (Cnr2) N-acylphosphatidylethanolamine specific phospholipase D
(Nape-pld) and diacylglycerol lipase (Dagla) did not show any significant changes in (A) somatosensory cortex, (B) thalamus, or (C) articular tissue. Beta-actin was
used as housekeeping gene. mRNA levels were determined by RT-PCR. All data show median, percentile 75, percentile 25, min. and max. of at least 6 to 15 mice.
Groups were compared using Kruskal–Wallis test followed by Mann–Whitney test. ∗p < 0.05 vs. ipsilateral/vehicle.
of CFA, with the subsequent development of monoarthritis-like
conditions. Consecutive treatment for 3 days with 10 mg/kg of
WOBE437 significantly attenuated allodynia and edema induced
during monoarthritis. The allodynia was already reduced by
single injection of 10 mg/kg of WOBE437. In models of
CFA-induced persistent inflammatory pain, the antiallodynia
effects of cannabinomimetics such as WIN55212-2, AM404,
and ajulemic acid, have been previously shown to be mediated
either via cannabinoid CB1 receptors or cannabinoid CB2
receptors (Mitchell et al., 2007; Vann et al., 2007; Li et al.,
2017). Moreover, both cannabinoid CB1 and CB2 receptors
have shown to be involved in the antiallodynic effect of
JZL195, a dual inhibitor of AEA and 2-AG degradation
(Anderson et al., 2014), suggesting a pleotropic multi-target
mechanism associated to the simultaneous increase of both
AEA and 2-AG levels (Di Marzo and De Petrocellis, 2012;
Pertwee, 2015; Pistis and O’Sullivan, 2017). Given the fact that
WOBE437 inhibits the reuptake of both AEA and 2-AG, we
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wondered whether the pharmacological action resembles the
one observed with JZL195, but with a different mechanism of
action. Interestingly, the selective and independent blockage of
either, CB1 receptor, CB2 receptor or PPARγ fully reversed the
antiallodynic effect induced by the treatment with WOBE437
for 3 days. Similarly, the antiinflammatory effect of WOBE437
(3 days of treatment), measured by the reduction of the knee
diameter (edema), was partially and independently reversed
by all three receptor antagonists. However, in the single dose
treatment with WOBE437, only the selective CB2 receptor
antagonist SR144528 and the TRPV1 antagonist capsazepine
were able to fully block the antiallodynic effect of WOBE437,
while selective antagonists of CB1 receptor and PPARγ did not
achieve a significant reduction. Because AEA is the endogenous
TRPV1 agonist (Smart et al., 2000) and capsazepine was able to
block the effect of WOBE437 in the single dose treatment we
assume that the increase of AEA levels induced by WOBE437 in
the somatosensory cortex caused the underlying pharmacology.
Analgesic effects of TRPV1 agonist have been reported after
central activation of TRPV1 receptor channels within the
descending antinociceptive pathway (Starowicz et al., 2007a;
Mascarenhas et al., 2015), which includes spinal and supraspinal
structures, such as PAG and rostral ventromedial medulla
(RVM). In addition, intrathecal or intra-PAG administration
of AEA have shown to induce antinociceptive or antiallodynia
effects through TRPV1 activation (Maione et al., 2006; Horvath
et al., 2008; Starowicz et al., 2012). In the CFA monoarthritis
model, TRPV1 have shown to mediate analgesic effects by
integrating different stimuli (Szabó et al., 2005). In addition, the
expression of TRPV1 in cortical neurons and their functional
role in modulating synaptic activity was recently described in
mice suffering from neuropathic pain (Marrone et al., 2017).
Furthermore, it has been propose that intra-PAG administration
of capsaicin induce an antinociceptive response involving the
activation of presynaptic TRPV1 receptors in glutamatergic
neurons, activation of postsynaptic mGlu5 receptors, release of 2-
AG via diacylglycerol lipase activation, activation of presynaptic
CB1 receptor and inhibition of GABA release, which leads
to disinhibition of the descending pain inhibitory pathway
(Liao et al., 2011). On the other hand, it has also been
reported that high concentrations of AEA at the peripheral
level leads to nociception or hyperalgesia via TRPV1 receptors
on primary sensory neurons, while low concentrations leads to
antinociception via CB1 receptor (Gauldie et al., 2001; Morisset
et al., 2001; Starowicz et al., 2007b). According to this reports, we
assume an influence of the supraspinal TRPV1 receptors on the
antiallodynia effects of WOBE437, rather than TRPV1 activation
at the peripheral level. This hypothesis is in agreement with
the present results, where AEA increases in the somatosensory
cortex but decreases in plasma. It has been shown that subtle
increments (1.2–1.5 times) in AEA levels in spinal cord or in PAG
are enough to observe the antinociceptive or antiallodynia effects
through TRPV1 activation (Maione et al., 2006; Starowicz et al.,
2012). However, a proper measurement of AEA levels in the PAG
and synovial tissue would be required to make any conclusions.
Our data also show the involvement of CB2 receptors in the
antiallodynic effect of WOBE437 which is fully prevented also
by the selective CB2 receptor antagonist SR144528. Activation
of CB2 receptor has been shown to counteract inflammatory
pain, e.g., in models of neuropathic pain (Racz et al., 2008;
Davis, 2014; Klauke et al., 2014). Interestingly, upon single
administration p.o., WOBE437 induced a significant increase of
2-AG level in plasma. Since 2-AG is considered the endogenous
full agonist at CB2 receptors (Gonsiorek et al., 2000; Soethoudt
et al., 2017), we can speculate that the antiallodynic effect
observed after single administration of WOBE437 reflects the
pleiotropic biological actions of both ECs, specifically through
the activation of TRPV1 (AEA) and CB2 receptors (2-AG). In
the 3 days WOBE437 treatment we could not use the TRPV1
antagonist capsazepine because the mice showed an unexpected
hypersensitivity, which appeared to be caused by concomitant
WOBE437 and capsazepine administration. Our data suggest that
the potentiation of EC signaling obtained by blocking cellular EC
reuptake, and potentially interfering with AEA trafficking in a
bidirectional manner (vide infra), leads to alleviation of allodynia
by a common potentially synergistic signaling pathway activated
by cannabinoid CB2 and CB1 receptors, PPARγ and possibly
TRPV1. On the other hand, the antiinflammatory effect seems
to be associated to more than one mechanism of action in which
activation of CB2 receptors is predominant. Thus, EC signaling
through CB1 receptor and PPARγ activation might only partially
contribute to the antiinflammatory effect in this mouse model of
monoarthritis. Since WOBE437 after 3 days treatment did not
influence transcription of CB receptors or the enzymes involved
in the generation of ECs we excluded indirect effects on gene
expression of the major proteins of the ECS.
A possible common signaling node activated by cannabinoid
CB1, CB2, and PPARγ receptors could be at the transcriptional
level. In animal models of adjuvant-induced arthritis,
osteoarthritis and neuroinflammation, it has been observed
that independent activation of CB2 receptor and PPARγ can
inhibit the activation of the canonical transcription factor
NF-κB (Fakhfouri et al., 2012; Saravanan et al., 2014) and
the mitogen-activated protein kinases (MAPKs) (Li et al.,
2013; Moens et al., 2013; Ribeiro et al., 2013; Ma et al., 2015).
This inhibition attenuates the expression and final release of
pro-inflammatory mediators such tumor necrosis factor-α,
interleukin 1-β, but also iNOS and COX2 (Fakhfouri et al.,
2012; Luo et al., 2014), which are associated with the pain
sensitization and the edema formation seen after CFA injection
(Khan et al., 2013; Li et al., 2013; Luo et al., 2014). On the
other hand, activation of cannabinoid CB1 receptors can also
modulate NF-κB and MAPKs pathways via upregulation of the
transcriptional activity of PPARγ (Du et al., 2011; Carroll et al.,
2012; Fakhfouri et al., 2012; Ignatowska-Jankowska et al., 2014).
In addition, ECs have been shown to modulate the activation
of PPARγ through three possible mechanisms: (1) direct
binding/activation, (2) via metabolites generated after AEA and
2-AG degradation, or (3) via cannabinoid CB1/CB2 receptor-
mediated downstream signaling (i.e., MAPKs) (Burstein, 2005;
O’Sullivan, 2007; O’Sullivan and Kendall, 2010). Therefore, ECs
might modulate the inflammatory stage in monoarthritic mice
through the inhibition of NF-κB/MAPKs signaling pathways,
as a plausible explanation of the indirect polypharmacological
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effects of WOBE437 after 3 days of treatment. Nevertheless,
further experiments are necessary to understand the exact
molecular mechanism. There are not direct reports about the
involvement of PPARγ in the pharmacological effects of MAGL
or FAAH inhibitors in vivo. However, in an in vitro model of
neuroinflammation, the pharmacological effects of the MAGL
inhibitor JZL184 and the FAAH inhibitor URB597 were shown to
be mediated by PPARγ in a CB1 receptor-depended manner (Du
et al., 2011). In addition, the antidyskinetic effects of URB597 in
combination with capsazepine were reversed by a non-selective
PPAR antagonist, and in the same model a PPARγ selective
agonist showed a significant reduction of dyskinesia (Martinez
et al., 2015). Conversely, in an acute model of carrageenan-
induced inflammatory hyperalgesia, PPARα but not PPARγ was
involved in the analgesic effects of URB597 (Jhaveri et al.,
2008). These reports might suggest that PPARγ is primarily
involved in chronic but not acute inflammatory conditions
(Villapol, 2018). Thus, cannabinoid receptors and PPARγ may
potentially constitute a synergic antiinflammatory signaling
network. The pharmacological differences between WOBE437
and FAAH/MAGL inhibitors could involve tissue selectivity, the
degree of increment in ECs levels and the differential extracellular
EC accumulation leading to increased cannabinoid CB1 and CB2
receptor activation. However, the present data point toward a
more complex action of WOBE437 as also the intracellular AEA
receptors TRPV1 and PPARγ were involved in the analgesic
effects of this EC reuptake inhibitor, accompanied by a weak
but significant decrease of AEA in plasma. Therefore, we cannot
exclude bidirectional transport effects in vivo as shown previously
in vitro (Chicca et al., 2012; Nicolussi and Gertsch, 2015).
CONCLUSION
The novel EC reuptake inhibitor WOBE437 not only exhibits
a high potency and selectivity (Chicca et al., 2017) but
also matches the bioavailability criteria (in mice) that depict
an adequate pharmacological tool compound. By applying
WOBE437 in different mouse models of pain and inflammation,
we found that the inhibition of EC reuptake triggers differential
effects via elevation of ECs in different tissues and distinct
pathophysiological/nociceptive contexts. This is in strong
agreement with data obtained from the dual inhibition of AEA
and 2-AG degradation (Anderson et al., 2014). Moreover, our
data obtained with WOBE437 treatment reveal the noteworthy
polypharmacology mediated by cannabinoid CB2, CB1, TRPV1,
and PPARγ receptors in a mouse monoarthritis pain model. This
indicates that this class of ECS modulators has the potential to
exert therapeutic effects in chronic inflammatory conditions in
which the pleiotropic effects of AEA and 2-AG counteract the
pathophysiology. Therefore, SERIs together with non-selective
FAAH/MAGL inhibitors are promising indirect cannabimimetics
and should be further investigated in preclinical models of
chronic inflammatory pain.
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